Shingrix access expansion welcomed

Patient groups back improved NIP access to Shingrix for primary and secondary immunodeficient patients aged 18 years and older  The Government’s decision to extend access to Shingrix for anyone aged 18 years and over considered at increased risk of herpes zoster due to an underlying condition and/or immunosuppressive treatments, through the National Immunisation Program (NIP)